(PharmaNewsWire.Com, May 21, 2019 ) According to the new market research report Defibrillators Market is projected to reach USD 10.88 Billion by 2022 from USD 9.32 Billion in 2017, growing at a CAGR of 3.1%. Factors such as technological advancements in defibrillators, rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training & awareness programs on defibrillators are expected to propel the growth of this market. Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=549 As of 2016, some of the prominent players in the defibrillators market were Medtronic (Ireland), St. Jude Medical (US), Boston Scientific (US), Philips (Netherlands), ZOLL Medical (US), BIOTRONIK (Germany), Physio-Control (US), Cardiac Science (US), LivaNova (UK), Nihon Kohden (Japan), SCHILLER (Switzerland), Mindray Medical (China), Mediana (South Korea), METRAX (Germany), and METsis (Turkey). Analysis of the market developments between 2014 and 2017 show that product launches & approvals was the most widely adopted growth strategy by players in the market. Players adopted this strategy to strengthen their market position. In 2016, Medtronic (Ireland) held the leadership position in the global ICDs market. The company has a broad product portfolio, a strong geographical presence, and a wide customer base in emerging economies, including Brazil, Russia, India, and China. To maintain its leadership position in the market, the company has been focusing on technological advancements in implantable defibrillators. In line with this strategy, the company launched Visia AF MRI SureScan CRT-D, Visia AF single-chamber ICDs, Claria MRI Quad CRT-D SureScan, Amplia MRI Quad CRT-D SureScan, Compia MRI Quad CRT-D SureScan, and Evera MRI SureScan ICD in the last three years. To capture growth opportunities in the emerging the Asia Pacific region, the company set up its Asia-Pacific headquarters in Singapore, in 2016. Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549 ZOLL Medical (US) held the leadership position in the global external defibrillators market. Over the past three years, the company adopted new product launches, agreements, and partnerships as its core business strategies to enhance its share in the global external defibrillators market. For instance, in 2017, the company received FDA (US) premarket approval for its Hospital Wearable Defibrillator. Furthermore, the company entered into strategic agreements with various industry players in order to develop innovative defibrillators and incorporate advanced technologies. The company also focuses on partnerships to increase its geographical presence.
Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 newsletter@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
